Reported Sunday, Whitehawk's Real-World Data Show PTK7 Expression Remains Stable After Standard-Of-Care Therapies, Reinforcing Rationale For HWK-007 In EGFR Wild-Type NSCLC
PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a Target in Second- or Later-Line EGFR NSCLCFindings Reinforce the Scientific Rationale for HWK-007, Whitehawk's
Whitehawk found that a protein called PTK7 stays present in lung cancer patients even after standard treatments. This supports their plan to test a new drug called HWK-007 that targets this protein.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.